Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 11/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3558414 | 1.00 | SLC6A9 (0.44) | SLC6A9MAPTSIGMAR1ALDH1A1HPGD | |
| SCHEMBL3556320 | 0.82 | SLC6A9 (0.43) | SLC6A9MAPTSIGMAR1ALDH1A1HPGD | |
| SCHEMBL3436282 | 0.80 | SLC6A9 (0.53) | SLC6A9MAPTALDH1A1 | |
| SCHEMBL3436283 | 0.80 | SLC6A9 (0.53) | SLC6A9MAPTALDH1A1 | |
| SCHEMBL3547075 | 0.79 | SLC6A9 (0.43) | SLC6A9MAPTSIGMAR1CHRM1 | |
| SCHEMBL2641396 | 0.72 | HTR1A (0.36) | — | |
| SCHEMBL3554355 | 0.70 | ALDH1A1 (0.46) | MAPTALDH1A1HPGDSMN1; SMN2ELANE | |
| SCHEMBL16307945 | 0.69 | ALDH1A1 (0.47) | MAPTALDH1A1HPGDSMN1; SMN2ADRB1 | |
| SCHEMBL13999774 | 0.69 | SIGMAR1 (0.42) | MAPTSIGMAR1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL25124632 | 0.68 | CHRNB2 (0.46) | ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | GPR17, NTRK1, TRPV1 | SLC6A9 3516/4885MAPT 1330/4885SIGMAR1 1460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.